Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Merck & Co Inc (NYSE: MRK) was $84.93 for the day, up 0.84% from the previous closing price of $84.22. In other words, the price has increased by $0.84 from its previous closing price. On the day, 14.04 million shares were traded. MRK stock price reached its highest trading level at $85.8 during the session, while it also had its lowest trading level at $84.425.
Ratios:
Our analysis of MRK’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 24.48 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.41. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.42. In the meantime, Its Debt-to-Equity ratio is 0.72 whereas as Long-Term Debt/Eq ratio is at 0.69.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $85.
Deutsche Bank Downgraded its Buy to Hold on February 18, 2025, whereas the target price for the stock was revised from $128 to $105.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 25 ’25 when Smart Dalton E. III sold 4,262 shares for $82.76 per share. The transaction valued at 352,723 led to the insider holds 7,778 shares of the business.
DALTON SMART bought 4,262 shares of MRK for $352,723 on Apr 25 ’25. On Feb 19 ’25, another insider, Oosthuizen Johannes Jacobus, who serves as the President, U.S. Market of the company, sold 8,500 shares for $84.09 each. As a result, the insider received 714,745 and left with 30,705 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRK now has a Market Capitalization of 212136460288 and an Enterprise Value of 237210304512. As of this moment, Merck’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.09, and their Forward P/E ratio for the next fiscal year is 8.82. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.17. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.34 while its Price-to-Book (P/B) ratio in mrq is 4.34. Its current Enterprise Value per Revenue stands at 3.729 whereas that against EBITDA is 8.373.
Stock Price History:
The Beta on a monthly basis for MRK is 0.38, which has changed by -0.2680341 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, MRK has reached a high of $120.30, while it has fallen to a 52-week low of $73.31. The 50-Day Moving Average of the stock is 4.42%, while the 200-Day Moving Average is calculated to be -4.12%.
Shares Statistics:
MRK traded an average of 14.13M shares per day over the past three months and 10112650 shares per day over the past ten days. A total of 2.50B shares are outstanding, with a floating share count of 2.50B. Insiders hold about 0.10% of the company’s shares, while institutions hold 80.06% stake in the company. Shares short for MRK as of 1753920000 were 25879122 with a Short Ratio of 1.83, compared to 1751241600 on 35092687. Therefore, it implies a Short% of Shares Outstanding of 25879122 and a Short% of Float of 1.15.
Dividends & Splits
With its trailing 12-month dividend rate of 3.16, MRK has a forward annual dividend rate of 3.20. Against a Trailing Annual Dividend Yield of 0.03752078The stock’s 5-year Average Dividend Yield is 3.01. The current Payout Ratio is 46.32% for MRK, which recently paid a dividend on 2025-06-16 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 2021-06-03 when the company split stock in a 1048:1000 ratio.
Earnings Estimates
As of right now, 15.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $2.21, with high estimates of $2.27 and low estimates of $2.13.
Analysts are recommending an EPS of between $9.13 and $8.79 for the fiscal current year, implying an average EPS of $8.93. EPS for the following year is $9.61, with 24.0 analysts recommending between $10.27 and $8.48.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 16 analysts. It ranges from a high estimate of $17.37B to a low estimate of $16.61B. As of the current estimate, Merck & Co Inc’s year-ago sales were $16.66BFor the next quarter, 16 analysts are estimating revenue of $16.32B. There is a high estimate of $16.59B for the next quarter, whereas the lowest estimate is $15.95B.
A total of 25 analysts have provided revenue estimates for MRK’s current fiscal year. The highest revenue estimate was $65.39B, while the lowest revenue estimate was $64.09B, resulting in an average revenue estimate of $64.75B. In the same quarter a year ago, actual revenue was $64.17BBased on 24 analysts’ estimates, the company’s revenue will be $67.91B in the next fiscal year. The high estimate is $70.88B and the low estimate is $65.5B.
